Repare Therapeutics Inc (RPTX)
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business